AzTrials
AzTrials

Periodontal RegenerationNCT06694168

Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects

A study testing Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery and REGEND001 Autologous Therapy Product in people with Periodontal Regeneration and Minimally Invasive Surgical Technique, run by Universidad de los Andes, Chile at 1 site in Chile.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate the efficacy of using L-PRF (leukocyte and platelet rich fibrin clot) as an autologous filling material in conjunction with the EPP (entire papilla preservation) technique for the treatment of interproximal intraosseous periodontal defects, compared to the same technique… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery and REGEND001 Autologous Therapy Product
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChile
Study dates
27 Aug 2024to 30 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients diagnosed with periodontal disease (loss of interproximal clinical attachment loss in 2 non-adjacent teeth or clinical attachment loss of ≥3mm associated with a PD \>3 mm in two or more teeth) will be included.
  • After re-evaluation (6 weeks after non-surgical periodontal therapy) presented residual probing depths equal to or greater than 6 mm.
  • Residual pocket is associated with interproximal intrabony periodontal defects of at least 2 walls, with a depth ≥ 3 mm and an angulation ≤ 40º determined on a periapical radiograph.

Who cannot join

  • Patients with an underlying decompensated pathology such as diabetes and hypertension.
  • Patients taking medications that interfere with the healing process such as bisphosphonates.
  • Patients with diseases that alter bone metabolism such as osteoporosis.
  • Pregnant or breastfeeding women.

Trial locations and contacts

1 site in 1 country.

Chile1 site, 1 recruiting
  • CESA (centro de salud de la clínica odontológica de la Universidad de los Andes)

    Santiago, San Bernardo, 8050000

    Guillermo E Salgado, DDS, +56225891100 ext. +562, gsalgado@uandes.cl

    Andreas G Anwandter, DDS

    Recruiting

Other trials in Chile

About this study

Official title: Efficacy of the Entire Papilla Preservation Technique With and Without the Use of L-PRF as a Regenerative Material for the Treatment of Infrabony Defects: A Randomized Controlled Clinical Trial

The goal of this clinical trial is to evaluate the efficacy of using L-PRF (leukocyte and platelet rich fibrin clot) as an autologous filling material in conjunction with the EPP (entire papilla preservation) technique for the treatment of interproximal intraosseous periodontal defects, compared to the same technique without L-PRF regarding clinical periodontal parameters and obtained radiographic parameters. It will also report possible postoperative complications and evaluate postoperative sensitivity. The main questions it aims to answer is:

  • What is the effectiveness of LPR-F in conjunction with a complete papilla preservation (EPP) technique for the treatment of intrabony periodontal defects in CESA (health care center) patients in terms of clinical and radiographic periodontal parameters compared to the use of the same technique without L-PRF?

A non-randomized controlled clinical trial will be conducted on patients at CESA of the Universidad de los Andes. In 30 patients, 30 periodontal defects associated with a pocket with probing depths equal to or greater than 6 mm will be treated using the complete papilla preservation technique, either with L-PRF filling or without any filling material, assigned randomly to each intervention (15 participants in each group). Researchers will evaluate clinical and radiographic parameters at baseline and 6 months post-surgery. Patients will report their level of pain 24 hours and 7 days after surgery.

Read the detailed description

Periodontitis is an infectious disease of bacterial origin that leads to a slow and progressive loss of periodontal attachment, resulting in the destruction of supporting tissues and the formation of periodontal pockets. These pockets can be classified as suprabony or intrabony, with the latter being those where the bottom of the pocket is apical to the level of the adjacent alveolar bone and the bone loss presents a vertical pattern. Intraosseous defects affect 36% of periodontal patients and are particularly challenging to treat due to their association with greater loss of periodontal support, increased clinical attachment loss, deeper probing depths, greater tooth mobility, and functional consequences for the patient; thus, they have a less favorable prognosis and response to non-surgical periodontal treatment.

Lang et al. established that periodontal defects can be successfully treated with non-surgical therapy, limiting additional surgical interventions to sites with an initial probing depth of 6 mm or more, or to advanced periodontal lesions that, after a successful etiological phase, still retain residual pockets ≥ 6 mm. Given this, surgical periodontal therapy becomes a therapeutic alternative for intraosseous defects associated with advanced periodontal destruction, aiming to reduce tooth loss over time, recover lost periodontal support, and improve patient's quality of life.

Different surgical alternatives have been developed to enhance short- and long-term clinical outcomes in teeth with infrabony defects and reduced periodontal support. If the contour of the existing bone and the number of remaining bony walls are favorable, regenerative surgical therapy could successfully regenerate bone up to the level of the alveolar crest. The use of materials such as a demineralized allogeneic bone matrix in guided tissue regeneration has shown to achieve reductions in probing depths, gains in clinical attachment level, and filling of treated defects compared to defect instrumentation through open flap debridement.

However, these treatment modalities are sensitive to technique, and their outcomes depend on various factors including patient-dependent factors such as plaque control and smoking habits; site-specific factors, such as defect morphology; and factors inherent to the surgical techniques employed. Consequently, the failure of conventional surgical techniques, such as early exposure of the regenerated area, has been reported in the scientific literature and is even more frequent with the use of membranes and bone substitutes.

In light of this, innovations in flap design and soft tissue management have reduced failures associated with early wound closure. Surgical techniques such as simplified papilla flap and modified techniques, minimally invasive surgical technique (MIST), and modified minimally invasive surgical technique (M-MIST) have been designed to protect the regeneration site and facilitate the stability of the blood clot.

Recently, the complete papilla preservation technique has been proposed for treating intraosseous defects through regeneration, with a surgical approach designed to fully preserve the integrity of the interdental papilla, thus achieving an optimal environment for wound healing. Full access to the defect is achieved through a tunnel incision with vertical release and the elevation of a short flap on the contralateral side of the tooth associated with the defect. Then, enamel matrix derivatives and bone substitutes are applied to the defect to promote periodontal regeneration at the site. Although the evidence supporting the success of this technique is limited, in 2020 Aslan et al. compared the outcomes of using this technique with and without biomaterials for filling the defect. They reported no statistically significant differences in clinical attachment gain, probing depth reduction, or increase in gingival recession between the groups treated with the complete preservation technique and filling material or with the technique alone, respectively. They concluded that the use of this technique with and without regeneration materials resulted in improvements in the clinical and radiographic parameters of the treated defects.

The search for different materials with regenerative potential has led to the use of L-PRF (leukocyte and platelet rich fibrin), an autologous platelet-rich fibrin and leukocyte concentrate derived from blood that stimulates, enhances, and accelerates healing through a centrifugation process. The growth factors present in the concentrates, along with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes, and stem cells, L-PRF regulates the immune response by controlling inflammation, with a continuous release of growth factors and an analgesic effect, providing greater postoperative comfort to the patient. Additionally, being an autologous product significantly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs, and ease of preparation, it is widely used in the periodontal surgical field.

One of the goals of treating infrabony defects is the regeneration of soft and hard tissues, which is why using a complete papilla preservation surgical technique along with L-PRF as a biomaterial is a minimally invasive alternative to achieve this. The properties of L-PRF mentioned above will improve the biological conditions of the site and reduce postoperative complications, making its use in regenerative periodontal therapy worthy of deeper investigation. This is even more relevant given the lack of studies reporting the use of L-PRF associated with this surgical technique.

The aim of this study is to evaluate the efficacy of using a papilla preservation technique for the treatment of interproximal infrabony periodontal defects, with and without the additional use of L-PRF, concerning clinical and radiographic parameters. Its importance is based on the need in the field of periodontology to find minimally invasive, effective, and low-cost surgical techniques with the least amount of postoperative complications that allow for the treatment of infrabony defects in teeth affected by severe periodontitis, a growing public health issue. Improvements in clinical parameters through this procedure will translate into a greater likelihood of long-term tooth retention and an improvement in the patient's quality of life.

In order to achieve this, the following research question will be addressed: What is the efficacy of LPR-F in conjunction with a complete papilla preservation (EPP) technique for the treatment of infrabony periodontal defects in CESA patients in terms of clinical and radiographic periodontal parameters in comparison with the same technique, but without the use of L-PRF? All patients diagnosed with periodontal disease (loss of interproximal clinical attachment loss in 2 non-adjacent teeth or clinical attachment loss of ≥3mm associated with a probing depth of 3 mm in two or more teeth) will be included, who after re-evaluation 6 weeks after non-surgical periodontal therapy presented residual probing depths equal to or greater than 6 mm associated with interproximal intrabony periodontal defects of at least 2 walls, with a depth ≥ 3 mm and an angulation ≤ 40º determined on a periapical radiograph. Patients with underlying untreated pathologies such as diabetes and hypertension, patients taking medications that interfere with the healing process such as bisphosphonates, diseases that alter bone metabolism such as osteoporosis, and pregnant or breastfeeding women will be excluded. 30 patients (30 defects) will be randomly allocated into an interventional group for the treatment of the infrabony defect. One group will be treated with an EPP technique using L-PRF as the defect filling material and the other group will be treated with the same technique, but with no biomaterial to fill the defect.

The clinical parameters that will be evaluated in each group will be: O'Leary Bacterial Plaque Index (PI), bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL), gingival margin position (GMP), distance from the interproximal contact point to the papilla tip (PP), papilla width (PW), and keratinized gingiva width (KW). These parameters will be measured before the surgical procedure and 6 months after surgery.

The radiographic measurements will be obtained by calibrated operators and will be analyzed in all subjects from a CBCT performed before surgical treatment and 6 months postoperatively. The infrabony component of the defect (INFRA) will be measured, allowing the calculation of the defect filling percentage after surgery (%DF). Additionally, measurements of the mesiodistal width (M-D) and buccal-palatal/lingual width (B-P/L) will be obtained. Researchers will evaluate clinical and radiographic parameters at baseline and 6 months post-surgery. Patients will report their level of pain 24 hours and 7 days after surgery.

The relevance of the present study is based on the need in the field of periodontics to find minimally invasive, effective and low-cost surgical techniques with the least amount of post-surgical complications that will successfully treat infrabony defects of teeth affected by severe periodontitis, a growing public health issue. Improvements in clinical parameters through this procedure will result in a greater likelihood of long-term tooth retention and an improvement in quality of life for the patient.

Being tested
Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery, REGEND001 Autologous Therapy Product
Keywords
Periodontitis, Guided Tissue Regeneration, Microsurgery, Bone Regeneration, Treatment Outcome, Intrabony defect, minimally invasive surgical technique, Entire papilla preservation
Medical subject headings
Periodontal Diseases, Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgeryProcedure or surgery

    The Entire Papilla Preservation Technique (EPP) is a minimally invasive surgical approach for the treatment of intraosseous defects allowing access to the defect maintaining the integrity of the interproximal papilla. Studies have evaluated its efficacy for the regeneration of intraosseous periodontal defects with or without the use of regenerative biomaterials to fill the defect.

  • REGEND001 Autologous Therapy ProductProcedure or surgery

    L-PRF is an autologous concentrate of platelet- and leukocyte-rich fibrin derived from blood, which through a centrifugation process allows to stimulate, improve and accelerate healing. The growth factors in the concentrates, together with pro-inflammatory and anti-inflammatory molecules, actively participate in the stimulation of the processes associated with tissue and bone repair and regeneration. Due to its high content of fibrin, platelets, leukocytes, monocytes and stem cells, L-PRF acts in immune regulation by controlling inflammation, with a continuous release of growth factors and presents an analgesic effect, which gives greater postoperative comfort to the patient. In addition, being an autologous product, it greatly reduces the risk of infection or rejection by the patient. Due to its beneficial biological effects, low costs and ease of preparation its use as a filling material in intraosseous defects will be evaluated.

Study groups in NCT06694168
Study groupRoleWhat they receive
EPP with L-PRF as a filling materialExperimentalThis group will have the infrabony defect treated with the use of an EPP minimally invasive technique and the defect will be filled with L-PRF.
Receives: Procedure: Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery; Procedure: REGEND001 Autologous Therapy Product
EPP with no defect filling materialActive comparatorThis group will have the infrabony defect treated with the use of an EPP minimally invasive technique, but the defect will not be filled with L-PRF.
Receives: Procedure: Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Probing depth

    Distance between the gingival margin and the bottom of the periodontal sulcus or pocket.

    Measured: From enrollment to the end of treatment 6 months postoperatively

  2. Clinical attachment level

    Distance between the cemento-enamel junction (CEJ) or a stable reference to the bottom of the periodontal pocket.

    Measured: From enrollment to the end of treatment 6 months postoperatively

  3. Bleeding on probing

    It will be evaluated dichotomously in 6 sites per tooth and will be defined as a percentage by dividing the sites that bleed on probing with the total number of sites examined multiplied by 100.

    Measured: From enrollment to the end of treatment 6 months postoperatively

  4. Distance from contact point to tip of papilla (PP)

    Distance between the interproximal contact point and the tip of the interproximal papilla

    Measured: From enrollment to the end of treatment 6 months postoperatively

  5. Keratinized Gingiva Width

    Distance between the tip of the interproximal papilla and the mucogingival line.

    Measured: From enrollment to the end of treatment 6 months postoperatively

  6. Infrabony component of the defect (INFRA)

    Determined by the subtraction between distance from CEJ to the bottom of the defect (BD) minus the distance from CEJ to the tip of the interproximal crest (IC)

    Measured: From enrollment to the end of treatment 6 months postoperatively

  7. Defect filling percentage after surgery (%DF)

    Measured by subtraction between distance from CEJ to the bottom of the defect (BD) minus the distance from CEJ to the tip of the interproximal crest (IC), allowing the calculation of percentage defect filling (%DF) after surgery

    Measured: From enrollment to the end of treatment 6 months postoperatively

  8. Mesiodistal width (M-D) of the defect

    Distance between the mesial and distal wall of the osseous defect

    Measured: From enrollment to the end of treatment 6 months postoperatively

  9. Buccal-palatal/lingual width (B-P/L) of the defect

    Distance between the bucal and palatal/lingual wall of the osseous defect in mm.

    Measured: From enrollment to the end of treatment 6 months postoperatively

Secondary outcomes (1)
  1. Patient reported outcome: Pain

    The intensity of pain (ordinal categorical variable) will be measured after surgical treatment using a visual analogue measurement scale (VAS) that will consist of a measurement 24 hours after surgery by telephone and one week after surgery in the clinical control.

    Measured: 24 hours after surgery and one week after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2024
  2. Study start27 Aug 2024
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion30 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
To calculate the sample size, statistically significant EVA values were taken from a previous series of cases in the same line of research. The values were analyzed using STATA software, resulting in an N of 26 patients (26 defects). Finally, a final N of 30 defects to be treated was established (1 defect per patient), overestimating the initial N in case of possible losses during the follow-up period. If there is more than one site per patient that needs to be treated, it will be decided randomly which site will be included in the study, treating all sites with the same technique. The sample was randomized using the digital STATA software, separating the sample into sites to be treated using the EPP technique with defect filling using LPRF (15 defects) and sites to be treated with the same technique but without LPRF (15 defects).
Masking
Single blind
Who is masked
Care provider
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06694168
Sponsor's protocol ID
CEC2024045
Status last verified
Sep 2024
First submitted
15 Nov 2024
Last updated
25 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: In order for the results of study to be published in ICMJE journals some information might be shared.

Questions about this trial

What is this clinical trial studying?

A study testing Periodontal Regeneration, clinical and radiographic results, modified minimal invasive surgery and REGEND001 Autologous Therapy Product in people with Periodontal Regeneration and Minimally Invasive Surgical Technique, run by Universidad de los Andes, Chile at 1 site in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Andreas G Anwandter, DDS (+56225891100 ext. +562, aanwandter@miuandes.cl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Probing depth (time frame: From enrollment to the end of treatment 6 months postoperatively). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in